24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Basic InformationLookupsLatest News
Survey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Unvaccinated Americans Want to Stay That Way: PollIt's Tick Season: Protect Yourself From Lyme DiseaseHigh-Tech Exoskeletons Improve Bowel Function in People With Spinal Cord Injury'Superbug' Fungus Spreads Among Vulnerable in Two U.S. CitiesVaccinations Start to Climb in States Hit Hard by Delta VariantAs Olympics Begin, Tokyo Posts Highest Number of New COVID Cases in Six MonthsVirtual Roller Coaster Ride Study Brings New Insights Into MigraineBiden Says Full Approval for COVID Vaccines Coming SoonPfizer Vaccine Offers 88% Protection Against Delta Variant, But 2 Doses NeededSecret Weapon: Why the 2nd Dose of Pfizer Vaccine Is So CrucialIn a First for the Continent, Pfizer COVID-19 Vaccine Will Be Produced in South AfricaLockdowns' Effects on Health Still Less Than Harm From Pandemic: ExpertsCOVID Drove Biggest Drop in U.S. Life Expectancy Since World War IIJ&J Vaccine Weak Against Delta Variant, 2nd Dose May Be NeededDouble Trouble: Wildfire Smoke Could Boost Odds for COVID's SpreadStatin Users May Have Added Protection Against Severe COVID-19Severe COVID in Kids: Rare, but Brain Issues Can ResultOne-Dose Blood Thinner Could Slash Blood Clot Risk After Knee ReplacementU.S. Issues Toughest Travel Alert for Britain As COVID Cases There ClimbPediatricians' Group: All School Kids, Staff Should Continue to Wear MasksGeneticists Probe Origins of Painful Cluster HeadachesAny COVID Infection Leaves Strong Antibody Levels in KidsMany Hit Hard by Pandemic Now Swamped by Medical DebtU.S. Surgeon General Backs Local Mask Mandates When NeededMake Summer Camp Safe for Your Child With Asthma, AllergiesCanada May Open Borders to Fully Vaccinated Americans by Mid-AugustCDC Advisors to Discuss 3rd COVID Vaccine Dose for ImmunocompromisedFDA to Prioritize Full Approval for Pfizer COVID VaccineEven a Little Lead in Drinking Water Can Harm People With Kidney DiseaseStatin's Health Benefits Far Outweigh  Any Potential Harms: StudyMore Than a Quarter of Long COVID Patients Still Not Recovered After 6 MonthsWhy Many Black & Hispanic Americans Distrust COVID VaccinesA Better Test to Help Spot Glaucoma?U.S. Surgeon General Issues Call to Counter 'Urgent Threat' of Vaccine MisinformationFriends, Family Key to Turning a 'No' on Vaccination to a 'Yes'AHA News: How Healthy Is Your Neighborhood? Where You Live Can Greatly Affect Heart, Brain HealthHeart Troubles Ease Over Time in Kids With MIS-CUltra-Processed Foods Might Help Drive Inflammatory Bowel DiseaseCOVID Antibodies From Vaccination Are Almost 3 Times Higher Than From InfectionHalf of U.S. Teens Plan to Get COVID Shot, But Can Numbers Go Higher?Many States Move to Ban Vaccine Mandates, Passports in Public SchoolsBusted Ankle? What's Better, a Cast or Brace?New COVID Cases Double in U.S. in Past Three WeeksAmericans With Diabetes Were Hit Hard by COVID PandemicAHA News: The Challenge of Diabetes in the Black Community Needs Comprehensive SolutionsInhaled COVID Vaccine Shows Promise in Animal TrialsFlu Shot Might Help Ward Off Severe COVIDCould Men's Testosterone Play Role in COVID Survival?Adults With ADHD May Face Higher Odds for Physical Illnesses: Study
Questions and AnswersLinks
Related Topics


What Works Best to Ease Migraines?

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Jun 16th 2021

new article illustration

WEDNESDAY, June 16, 2021 (HealthDay News) -- A new research review offers good news for migraine sufferers: There are more pain-relieving options than ever.

In an analysis of over 100 published studies, researchers found that several drug classes showed good evidence they ease the pain of a migraine-in-progress.

Some of those medications have only become available in the past few years, opening up new options for migraine sufferers who don't get enough relief from old standby drugs.

Experts said the widening field of migraine treatments, which also include nerve-stimulating devices, is encouraging.

"It's great news there are now many effective treatments available," said Dr. Rebecca Burch, a neurologist at Brigham and Women's Hospital in Boston.

For any one patient, she noted, finding the right treatment may take some trial-and-error — so persistence is key.

"Stick with it. Don't give up hope," Burch said. "If the first treatment doesn't work, that doesn't mean nothing will."

Burch co-wrote an editorial that accompanied the research review in the June 15 issue of the Journal of the American Medical Association.

The analysis — which looked at 115 clinical trials and 15 previous evidence reviews — offers a needed update, said lead author Dr. Juliana VanderPluym.

"Over the past three years or so, a number of new migraine therapies have become available," said VanderPluym, an assistant professor of neurology at the Mayo Clinic in Scottsdale, Ariz.

They include the oral medications lasmiditan (Reyvow), which acts on a receptor for the hormone serotonin; and two "gepants" called ubrogepant (Ubrelvy) and rimegepant (Nurtec).

Gepants interfere with CGRP, a small protein released by the trigeminal nerve that plays a key role in generating migraine misery.

The review found, unsurprisingly, strong evidence supporting long-used migraine treatments — namely, nonsteroidal anti-inflammatory drugs like ibuprofen (Advil, Motrin) and aspirin, and a class of migraine-specific drugs called triptans.

All of those medications beat placebos in reducing pain two hours into a migraine attack, and one day later.

Meanwhile, both lasmiditan and the gepants looked good when it came to reducing or erasing pain two hours into an attack, and one day later. (The strength of the evidence was graded as "moderate" to "high.")

But for the most part, triptans remain the first choice for treating acute migraines, Burch said.

Triptans work by targeting serotonin (in a different way than lasmiditan). They are often effective at dulling pain, but a downside is they constrict blood vessels. That means people at increased risk of heart attack or stroke typically cannot use them.

For some other patients, Burch said, triptans simply do not work, or the side effects — like numbness, dizziness and sleepiness — make them difficult to take.

That's where alternatives come in — though so, too, can the practical issues of cost and insurance coverage.

Both gepants and lasmiditan are expensive, VanderPluym pointed out.

So insurance plans, she said, often require patients to try two triptans, or sometimes more, before they will cover the pricier drugs.

Medications are not the only treatment option, though.

The review found that several nerve-stimulating devices outperformed "sham" devices in easing migraine pain. The gadgets are used at home and employ electric or magnetic pulses to stimulate certain nerves involved in pain signaling.

"Devices are a great option for patients who want to avoid medications, or as an add-on to medication," VanderPluym said.

But both she and Burch pointed to one barrier: cost. Insurance typically does not cover the devices, so patients can face high out-of-pocket expenses.

The review also highlights a medication class that should not be used for migraine pain — opioids.

The drugs, such as OxyContin and Vicodin, carry the risks of dangerous side effects and addiction. And when it comes to migraine pain, they simply do not work, Burch said.

The bottom line, according to VanderPluym, is that the "right" migraine treatment plan varies from person to person — and effectiveness, safety and cost all matter.

For people with longstanding migraines, she noted, this could be a good time to revisit their treatment plan with their doctor. Some might find the newer options are worth a try, VanderPluym said.

The study was funded by the U.S. Agency for Healthcare Research and Quality. VanderPluym has consulted for or received research funds from drugmakers Teva and Amgen.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on migraines.

SOURCES: Juliana VanderPluym, MD, assistant professor, neurology, Mayo Clinic, Scottsdale, Ariz.; Rebecca Burch, MD, neurologist, Brigham and Women's Hospital, and assistant professor, neurology, Harvard Medical School, Boston; Journal of the American Medical Association, June 15, 2021